



## Clinical trial results:

### A Randomized, Open-Label, Parallel-Group, Multi-Center Study of Adding Edoxaban or Clopidogrel to Aspirin to Maintain Patency in Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention - Edoxaban in Peripheral Arterial Disease (ePAD)

#### Summary

EudraCT number	2012-003009-88
Trial protocol	DE BE NL AT
Global end of trial date	03 December 2014

#### Results information

Result version number	v1
This version publication date	18 August 2016
First version publication date	18 August 2016

#### Trial information

##### Trial identification

Sponsor protocol code	DU176b-E-U210
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01802775
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Daiichi Sankyo Pharma Development
Sponsor organisation address	399 THORNALL STREET, Edison, New Jersey, United States, 08837
Public contact	Clinical Trial Information, Daiichi Sankyo Development Ltd, +44 1753482800, info@dsd-eu.com
Scientific contact	Clinical Trial Information, Daiichi Sankyo Development Ltd, +44 1753482800, info@dsd-eu.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 December 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	03 December 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate clinically relevant bleeding (that is, major or clinically relevant non-major bleeding) occurring during treatment or within 3 days of interrupting or stopping study drug and to evaluate re-stenosis/re-occlusion at the treated segment(s) measured at 1, 3 and 6 months after randomization using color coded duplex ultrasonography scanning (DUS).

Protection of trial subjects:

The safety assessments included clinical laboratory tests, Physical examination, vital signs and ECG variables. Adverse events were monitored throughout the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 February 2013
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	3 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 89
Country: Number of subjects enrolled	Switzerland: 25
Country: Number of subjects enrolled	Israel: 12
Country: Number of subjects enrolled	Netherlands: 13
Country: Number of subjects enrolled	Austria: 28
Country: Number of subjects enrolled	Belgium: 15
Country: Number of subjects enrolled	Germany: 21
Worldwide total number of subjects	203
EEA total number of subjects	77

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	63
From 65 to 84 years	133
85 years and over	7

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 275 subjects were screened, of these 203 subjects were randomized into the study, with 101 subjects in the edoxaban group and 102 subjects in the clopidogrel group.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Clopidogrel

Arm description:

Subjects administered with a loading dose of clopidogrel 300 milligram (mg) (four 75-mg tablets) as first dose within 4 hours of hemostasis followed by 75 mg once daily (QD) (one 75 mg tablet) orally for a total of approximately 3 months on a background of aspirin 100 mg enteric coated tablets QD.

Arm type	Active comparator
Investigational medicinal product name	Clopidogrel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects administered with a loading dose of clopidogrel 300 milligram (mg) (four 75-mg tablets) as first dose within 4 hours of hemostasis followed by 75 mg once daily (QD) (one 75 mg tablet) orally for a total of approximately 3 months.

Investigational medicinal product name	Aspirin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects administered with aspirin 100 mg enteric coated tablets QD orally as background treatment along with Clopidogrel for 3 months.

<b>Arm title</b>	Edoxaban
------------------	----------

Arm description:

Subjects administered with edoxaban 60 mg once daily (two 30 mg tablets) for approximately 3 months starting with the first dose given within 4 hours of hemostasis on a background of aspirin 100 mg tablets QD.

Arm type	Experimental
Investigational medicinal product name	Aspirin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects administered with aspirin 100 mg enteric coated tablets QD orally as background treatment

along with Edoxaban for 3 months.

Investigational medicinal product name	Edoxaban
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects administered with edoxaban 60 mg once daily (two 30 mg tablets) for approximately 3 months.

<b>Number of subjects in period 1</b>	Clopidogrel	Edoxaban
Started	102	101
Completed	96	89
Not completed	6	12
Physician decision	1	-
Consent withdrawn by subject	3	5
Adverse event, non-fatal	1	1
Death	-	3
Other	-	1
Lost to follow-up	1	2

## Baseline characteristics

### Reporting groups

Reporting group title	Clopidogrel
-----------------------	-------------

Reporting group description:

Subjects administered with a loading dose of clopidogrel 300 milligram (mg) (four 75-mg tablets) as first dose within 4 hours of hemostasis followed by 75 mg once daily (QD) (one 75 mg tablet) orally for a total of approximately 3 months on a background of aspirin 100 mg enteric coated tablets QD.

Reporting group title	Edoxaban
-----------------------	----------

Reporting group description:

Subjects administered with edoxaban 60 mg once daily (two 30 mg tablets) for approximately 3 months starting with the first dose given within 4 hours of hemostasis on a background of aspirin 100 mg tablets QD.

Reporting group values	Clopidogrel	Edoxaban	Total
Number of subjects	102	101	203
Age categorical Units: Subjects			
Adults (18-64 years)	33	30	63
From 65-84 years	68	65	133
85 years and over	1	6	7
Age continuous Units: years			
arithmetic mean	66.7	68	
standard deviation	± 8.55	± 10.36	-
Gender categorical Units: Subjects			
Female	24	34	58
Male	78	67	145

## End points

### End points reporting groups

Reporting group title	Clopidogrel
Reporting group description: Subjects administered with a loading dose of clopidogrel 300 milligram (mg) (four 75-mg tablets) as first dose within 4 hours of hemostasis followed by 75 mg once daily (QD) (one 75 mg tablet) orally for a total of approximately 3 months on a background of aspirin 100 mg enteric coated tablets QD.	
Reporting group title	Edoxaban
Reporting group description: Subjects administered with edoxaban 60 mg once daily (two 30 mg tablets) for approximately 3 months starting with the first dose given within 4 hours of hemostasis on a background of aspirin 100 mg tablets QD.	

### Primary: Percentage of Subjects with Re-stenosis/re-occlusion

End point title	Percentage of Subjects with Re-stenosis/re-occlusion
End point description: Percentage of subjects with re-stenosis/re-occlusion, defined as Duplex ultrasonography scanning (DUS) Peak systolic velocity ratio (PSVR) greater than or equal to 2.4, at the treated segment(s) at 1, 3, and 6 months, as read at VasCore. Modified Intent-to-Treat (mITT) Set 2 population included all randomized subjects who received at least 1 dose of the study drug and had at least 1 post-dose duplex scanning. Here 'n' indicates the number of subjects analysed at specific time point.	
End point type	Primary
End point timeframe: Months 1, 3 and 6	

End point values	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	99	96		
Units: percentage of subjects				
number (not applicable)				
Month 1 (n = 88, 90)	5.7	10		
Month 3 (n = 94, 93)	13.8	23.7		
Month 6 (n = 95, 94)	34.7	30.9		

### Statistical analyses

Statistical analysis title	Statistical analyses_Month 1
Comparison groups	Edoxaban v Clopidogrel

Number of subjects included in analysis	195
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	4.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	12.2

<b>Statistical analysis title</b>	Statistical analyses_Month 3
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	195
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	9.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	20.9

<b>Statistical analysis title</b>	Statistical analyses_Month 6
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	195
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.3
upper limit	9.5

**Primary: Percentage of subjects with Adjudicated Bleeding Events in the On-Treatment Period Based on International Society of Thrombosis and Haemostasis (ISTH)**

End point title	Percentage of subjects with Adjudicated Bleeding Events in the On-Treatment Period Based on International Society of Thrombosis and Haemostasis (ISTH)
-----------------	--

End point description:

Clinically relevant bleeding Major or Clinically relevant non-major (CRNM) Bleeding, Major Bleeding, Life-

threatening Bleeding, CRNM Bleeding, Minor Bleeding and Any Bleeding was assessed. Safety Analysis Set population included all subjects who received at least 1 dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

up to 3 months

End point values	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: percentage of subjects				
number (confidence interval 95%)				
Including Access Site Bleeding (IASB): Any Bleeding	27.7 (19.3 to 37.5)	30 (21.2 to 40)		
IASB: Major or CRNM Bleeding	7.9 (3.5 to 15)	11 (5.6 to 18.8)		
IASB : Major Bleeding	5 (1.6 to 11.2)	1 (0 to 5.4)		
IASB : Life-threatening Bleeding	2 (0.2 to 7)	1 (0 to 5.4)		
IASB : CRNM Bleeding	4 (1.1 to 9.8)	10 (4.9 to 17.6)		
IASB : Minor Bleeding	20.8 (13.4 to 30)	20 (12.7 to 29.2)		
Excluding Access Site Bleeding (EASB) Any Bleeding	22.8 (15 to 32.2)	25 (16.9 to 34.7)		
EASB : Major or CRNM Bleeding	5.9 (2.2 to 12.5)	6 (2.2 to 12.6)		
EASB : Major Bleeding	4 (1.1 to 9.8)	1 (0 to 5.4)		
EASB : Life-threatening Bleeding	2 (0.2 to 7)	1 (0 to 5.4)		
EASB : CRNM Bleeding	3 (0.6 to 8.4)	5 (1.6 to 11.3)		
EASB : Minor Bleeding	17.8 (10.9 to 26.7)	19 (11.8 to 28.1)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical analyses_ IASB: Major or CRNM Bleeding
-----------------------------------	--

Statistical analysis description:

Statistical analysis was compared for Including Access Site Bleeding (IASB) Major or Clinically relevant non-major (CRNM) Bleeding.

Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5
upper limit	11.2

<b>Statistical analysis title</b>	Statistical analyses_IASB: Major Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.6
upper limit	0.7

<b>Statistical analysis title</b>	SA_IASB: Life-threatening Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	2.4

<b>Statistical analysis title</b>	Statistical analyses_IASB: CRNM Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	13

<b>Statistical analysis title</b>	Statistical analyses_IASB: Minor Bleeding
-----------------------------------	---

Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.9
upper limit	10.3

<b>Statistical analysis title</b>	Statistical analyses_IASB: Any Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.2
upper limit	14.8

<b>Statistical analysis title</b>	Statistical analyses_ EASB: Major or CRNM Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.5
upper limit	6.6

<b>Statistical analysis title</b>	Statistical analyses_ EASB: Major Bleeding
Comparison groups	Edoxaban v Clopidogrel

Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.2
upper limit	1.3

<b>Statistical analysis title</b>	SA_EASB: Life-threatening Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	2.4

<b>Statistical analysis title</b>	Statistical analyses_EASB: CRNM Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.4
upper limit	7.4

<b>Statistical analysis title</b>	Statistical analyses_EASB: Minor Bleeding
Comparison groups	Edoxaban v Clopidogrel

Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.5
upper limit	11.9

<b>Statistical analysis title</b>	Statistical analyses_EASB: Any Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.6
upper limit	14

**Primary: Percentage of Subjects with Adjudicated Bleeding Events in the On-Treatment Period Based on Thrombolysis in Myocardial Infarction (TIMI)**

End point title	Percentage of Subjects with Adjudicated Bleeding Events in the On-Treatment Period Based on Thrombolysis in Myocardial Infarction (TIMI)
-----------------	--

End point description:

Clinically relevant bleeding Major or Clinically relevant non-major (CRNM) Bleeding, Major Bleeding, Life-threatening Bleeding, CRNM Bleeding, Minor Bleeding and Any Bleeding was assessed. Safety Analysis Set population included all subjects who received at least 1 dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Up to 3 months

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: percentage of subjects				
number (confidence interval 95%)				
Including Access Site Bleeding(IASB):Any Bleeding	8.9 (4.2 to 16.2)	5 (1.6 to 11.3)		
IASB : Major Bleeding	2 (0.2 to 7)	0 (0 to 0)		

IASB : Life-threatening Bleeding	2 (0.2 to 7)	0 (0 to 0)		
IASB : Minor Bleeding	2 (0.2 to 7)	3 (0.6 to 8.5)		
IASB : Minimal Bleeding	5 (1.6 to 11.2)	2 (0.2 to 7)		
Excluding Access Site Bleeding (EASB):Any Bleeding	6.9 (2.8 to 13.8)	2 (0.2 to 7)		
EASB : Major Bleeding	2 (0.2 to 7)	0 (0 to 0)		
EASB : Life-threatening Bleeding	2 (0.2 to 7)	0 (0 to 0)		
EASB : Minor Bleeding	1 (0 to 5.4)	2 (0.2 to 7)		
EASB : Minimal Bleeding	4 (1.1 to 9.8)	0 (0 to 0)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical analyses_ IASB: Major Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	0.7

<b>Statistical analysis title</b>	SA_ IASB:Life-threatening Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	0.7

<b>Statistical analysis title</b>	Statistical analyses_ IASB: Minor Bleeding
Comparison groups	Edoxaban v Clopidogrel

Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.3
upper limit	5.3

<b>Statistical analysis title</b>	Statistical analyses_ IASB: Minimal Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8
upper limit	2.1

<b>Statistical analysis title</b>	Statistical analyses_ IASB: Any Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.9
upper limit	3.1

<b>Statistical analysis title</b>	Statistical analyses_ EASB: Major Bleeding
Comparison groups	Edoxaban v Clopidogrel

Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	0.7

<b>Statistical analysis title</b>	SA_ EASB: Life-threatening Bleed
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	0.7

<b>Statistical analysis title</b>	Statistical analyses_ EASB: Minor Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	4.4

<b>Statistical analysis title</b>	Statistical analyses_ EASB: Minimal Bleeding
Comparison groups	Edoxaban v Clopidogrel

Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.8
upper limit	-0.2

<b>Statistical analysis title</b>	Statistical analyses_ EASB: Any Bleeding
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Risk difference (RD)
Point estimate	-4.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.6
upper limit	0.7

### Secondary: Change in Peak Systolic Velocity Ratio (PSVR) in the Treated Segment(s) at 3 and 6 Months Compared to 1 Month

End point title	Change in Peak Systolic Velocity Ratio (PSVR) in the Treated Segment(s) at 3 and 6 Months Compared to 1 Month
End point description: Change in Peak Systolic Velocity Ratio was evaluated. Modified Intent-to-Treat Set 1 population included all subjects who received at least 1 dose of the study drug. Here 'n' indicates the number of subjects analysed at specific time point.	
End point type	Secondary
End point timeframe: Month 1, 3 and 6	

End point values	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: ratio				
arithmetic mean (standard deviation)				
Month 1 (n= 72, 65)	1.47 (± 0.721)	1.61 (± 1.175)		
Change from Month 1 to Month 3 (n= 59, 50)	0.23 (± 0.683)	0.36 (± 1.074)		

Change from Month 1 to Month 6 (n= 49, 42)	0.81 (± 1.159)	0.9 (± 1.37)		
--	----------------	--------------	--	--

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change in Ankle-brachial index (ABI) at 3 and 6 months compared to 1 month

End point title	Change in Ankle-brachial index (ABI) at 3 and 6 months compared to 1 month
-----------------	--

End point description:

Ratio between the systolic pressure measured at the ankle and the systolic pressure measured in the arm as follows: Ankle: The systolic pressure will be measured in the index limb at the arteria dorsalis pedis and/or the arteria tibialis posterior. If both pressures are measured, the highest pressures will be used for the ABI calculation. Brachial: The systolic pressure will be measured in both arms, and the highest of both pressures will be used for the ABI calculation. Here 'n' indicates the number of subjects analysed at specific time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 1, 3 and 6

End point values	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: ratio				
arithmetic mean (standard deviation)				
Baseline (n= 100, 93)	0.69 (± 0.265)	0.67 (± 0.279)		
Month 1 (n= 93, 93)	0.97 (± 0.188)	0.93 (± 0.189)		
Change from Month 1 to Month 3 (n= 88, 84)	-0.05 (± 0.16)	-0.03 (± 0.148)		
Change from Month 1 to Month 6 (n= 83, 73)	-0.06 (± 0.213)	-0.03 (± 0.32)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects in Rutherford stage at 1, 3, and 6 months

End point title	Number of Subjects in Rutherford stage at 1, 3, and 6 months
-----------------	--

End point description:

Modified Intent-to-Treat Set 1 population included all subjects who received at least 1 dose of the study drug. Here 'n' indicates the number of subjects analysed at specific time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Months 1, 3 and 6

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: subjects				
number (not applicable)				
Month 1 (n=95, 97): Stage 0 (Asymptomatic)	59	51		
Month 1 (n=95, 97): Stage 1 (Mild Claudication)	24	23		
Month 1 (n=95, 97): Stage 2 (Moderate Claudication)	6	10		
Month 1 (n=95, 97): Stage 3 (Severe Claudication)	1	7		
Month 1 (n=95, 97): Stage 4 (Ischemic rest pain)	1	3		
Month 1 (n=95, 97): Stage 5 (Minor tissue loss)	4	3		
Month 1 (n=95, 97): Stage 6 (Ulceration or gangrene)	0	0		
Month 3 (n= 92, 88): Stage 0 (Asymptomatic)	62	55		
Month 3 (n= 92, 88): Stage 1 (Mild Claudication)	14	16		
Month 3 (n= 92, 88): Stage 2 (Moderate Claudication)	11	9		
Month 3 (n= 92, 88): Stage 3 (Severe Claudication)	2	5		
Month 3 (n= 92, 88): Stage 4 (Ischemic rest pain)	0	1		
Month 3 (n= 92, 88): Stage 5 (Minor tissue loss)	2	2		
Month 3 (n= 92, 88): Stage 6 (Ulceration or gangrene)	1	0		
Month 6 (n= 85, 78): Stage 0 (Asymptomatic)	48	40		
Month 6 (n= 85, 78): Stage 1 (Mild Claudication)	19	14		
Month 6 (n= 85, 78): Stage 2 (Moderate Claudication)	10	13		
Month 6 (n= 85, 78): Stage 3 (Severe Claudication)	6	10		
Month 6 (n= 85, 78): Stage 4 (Ischemic rest pain)	1	1		
Month 6 (n= 85, 78): Stage 5 (Minor tissue loss)	1	0		
Month 6 (n= 85, 78): Stage 6 (Ulceration or gangrene)	0	0		

## Statistical analyses

**Secondary: Number of Subjects with Targeted Clinical Events Adjudicated by Clinical Events Committee**

End point title	Number of Subjects with Targeted Clinical Events Adjudicated by Clinical Events Committee
End point description: Targeted Clinical Events included Symptomatic Acute Thrombosis Event, Target Lesion Revascularization Event, Amputation, Major adverse cardiovascular events (MACEs) - Non-Fatal yocardial Infarction (MI), Non-Fatal Stroke, CV-Death and Systemic Embolism Event. Modified Intent-to-Treat Set 1 population included all subjects who received at least 1 dose of study drug.	
End point type	Secondary
End point timeframe: Up to 6 months	

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: subjects				
number (not applicable)				
Symptomatic Acute Thrombosis Event	5	7		
Target Lesion Revascularization Event	10	11		
Amputation	4	1		
MACEs - Non-Fatal MI, Non-Fatal Stroke, CV-Death	1	3		
Systemic Embolism Event : Fatal	0	0		
Systemic Embolism Event : Non-fatal	0	0		
Myocardial Infarction (MI) event	1	2		
Death	0	3		

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical analyses_Symptomatic Acute Thrombosis
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Relative Risk
Point estimate	1.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.46
upper limit	4.31

<b>Statistical analysis title</b>	SA_Target Lesion Revascularization Event
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Relative Risk
Point estimate	1.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	2.5

<b>Statistical analysis title</b>	SA_Amputation
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Relative Risk
Point estimate	0.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.03
upper limit	2.22

<b>Statistical analysis title</b>	SA_Major Adverse Cardiovascular Events
Comparison groups	Edoxaban v Clopidogrel
Number of subjects included in analysis	201
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Relative Risk
Point estimate	3.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.32
upper limit	28.64

**Secondary: Number of Subjects with All-Cause Mortality Events During the Overall Study Period Adjudicated by Clinical Events Committee**

End point title	Number of Subjects with All-Cause Mortality Events During the Overall Study Period Adjudicated by Clinical Events Committee
-----------------	---

End point description:

Mortality was evaluated. Modified Intent-to-Treat Set 1 population included all subjects who received at least 1 dose of study drug.

End point type Secondary

End point timeframe:

up to 7 weeks after last dose administration

End point values	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: subjects				
number (not applicable)	0	3		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Plasma concentrations of edoxaban (DU-176) and its metabolite D21-2393

End point title Plasma concentrations of edoxaban (DU-176) and its metabolite D21-2393<sup>[1]</sup>

End point description:

Safety Analysis Set population included all subjects who received at least 1 dose of edoxaban. Here 'n' indicates the number of subjects analysed at specific time point.

End point type Secondary

End point timeframe:

Day 30 and Day 90

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Plasma concentration for Clopidogrel was not evaluated.

End point values	Edoxaban			
Subject group type	Reporting group			
Number of subjects analysed	100			
Units: nanogram per milliliter				
arithmetic mean (standard deviation)				
DU-176, Day 30 (n= 81)	132.066 (± 110.056)			
DU-176, Day 90 (n= 76)	129.053 (± 105.7143)			
D21-2393, Day 30 (n= 81)	12.3681 (± 15.45542)			
D21-2393, Day 90 (n=75)	11.2873 (± 11.63869)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Day 1 to Day 90 in anti-Factor Xa low-molecular-weight heparin (LMWH)

End point title	Change From Day 1 to Day 90 in anti-Factor Xa low-molecular-weight heparin (LMWH)
-----------------	---

End point description:

Change in anti-Factor Xa was assessed as a part of Pharmacodynamic analysis. Safety Analysis Set population included all subjects who received at least 1 dose of edoxaban. Here, 99999 indicates data was not evaluated at specific time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, 30 and 90

End point values	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: International units per millilitre arithmetic mean (standard deviation)				
Day 1 (n= 61, 60)	0.912 (± 0.8447)	0.803 (± 0.5937)		
Day 30 (n= 0, 86)	99999 (± 99999)	1.323 (± 1.0705)		
Day 90 (n= 0, 72)	99999 (± 99999)	1.351 (± 1.0105)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: DDimer

End point title	Pharmacokinetic or Pharmacodynamic Parameter: DDimer
-----------------	--

End point description:

Safety Analysis Set population included all subjects who received at least 1 dose of study drug. Units for Change From Day 1 to Day 90 in DDimer is milligram per litre (mg/L fibrinogen-equivalent units(FEU)).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, 30 and 90

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: milligram per litre (mg/L (FEU))				
arithmetic mean (standard deviation)				
Day 1 (n=95, 90)	1.149 (± 1.3628)	1.283 (± 1.7241)		
Day 30 (n= 86, 93)	1.022 (± 1.358)	0.837 (± 1.8743)		
Day 90 (n= 84, 85)	0.912 (± 1.0351)	0.932 (± 2.5883)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: Factor Xa

End point title	Pharmacokinetic or Pharmacodynamic Parameter: Factor Xa
-----------------	---

End point description:

Change in Factor Xa was assessed as a part of Pharmacodynamic analysis. Safety Analysis Set population included all subjects who received at least 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1, 30 and 90

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: percentage				
arithmetic mean (standard deviation)				
Day 1 (n= 95, 92)	102.5 (± 21.989)	101.24 (± 17.665)		
Day 30 (n= 86, 94)	116.25 (± 25.404)	73.09 (± 28.79)		
Day 90 (n= 85, 88)	114.7 (± 23.752)	75.47 (± 29.86)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: hs-C-Reactive Protein

End point title	Pharmacokinetic or Pharmacodynamic Parameter: hs-C-Reactive Protein
-----------------	---

End point description:

Change in hs-C-Reactive Protein was assessed as a part of Pharmacodynamic analysis. Safety Analysis

Set population included all subjects who received at least 1 dose of stud drug. 'n' indicates number of subjects evaluated at specific time point.

End point type	Secondary
End point timeframe:	
Day 1, 30 and 90	

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: milligram per litre				
arithmetic mean (standard deviation)				
Day 1 (n= 99, 99)	6.34 (± 10.75)	4.75 (± 7.88)		
Day 30 (n= 95, 96)	5.3 (± 6.602)	5.67 (± 8.254)		
Day 90 (n= 92, 88)	5.73 (± 13.127)	4.74 (± 8.657)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: International Normalized Ratio

End point title	Pharmacokinetic or Pharmacodynamic Parameter: International Normalized Ratio
-----------------	--

End point description:

Change in International Normalized Ratio was evaluated as a part of Pharmacodynamic analysis. Safety Analysis Set population included all subjects who received at least 1 dose of study drug. 'n' indicates number of subjects evaluated at specific time point.

End point type	Secondary
End point timeframe:	
Day 1, 30 and 90	

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: ratio				
arithmetic mean (standard deviation)				
Day 1 (n= 95, 91)	1.22 (± 0.482)	1.18 (± 0.548)		
Day 30 (n= 87, 89)	1 (± 0.229)	1.37 (± 0.367)		
Day 90 (n= 85, 85)	0.99 (± 0.185)	1.37 (± 0.512)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: P-Selectin

End point title | Pharmacokinetic or Pharmacodynamic Parameter: P-Selectin

End point description:

P-Selectin was evaluated as a part of Pharmacodynamic parameters. Safety Analysis Set population included all subjects who received at least 1 dose of study drug. 'n' indicates number of subjects evaluated at specific time point.

End point type | Secondary

End point timeframe:

Day 1, 30 and 90

End point values	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: nanogram per millilitre				
arithmetic mean (standard deviation)				
Day 1 (n= 101, 95)	43.16 (± 20.96)	45.4 (± 28.921)		
Day 30 (n= 93, 93)	41.19 (± 18.989)	43.48 (± 22.403)		
Day 90 (n= 87, 89)	41.91 (± 30.932)	43.45 (± 24.406)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: Partial Thromboplastin Time

End point title | Pharmacokinetic or Pharmacodynamic Parameter: Partial Thromboplastin Time

End point description:

Safety Analysis Set population included all subjects who received at least 1 dose of study drug. 'n' indicates number of subjects evaluated at specific time point.

End point type | Secondary

End point timeframe:

Day 1, 30 and 90

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: seconds				
arithmetic mean (standard deviation)				
Day 1 (n= 77, 80)	45.35 (± 37.66)	46.24 (± 33.985)		
Day 30 (n= 85, 93)	24.98 (± 2.341)	29.51 (± 9.181)		
Day 90 (n= 85, 86)	25.13 (± 2.209)	28.2 (± 5.767)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: Thrombin area under curve

End point title	Pharmacokinetic or Pharmacodynamic Parameter: Thrombin area under curve
End point description:	Safety Analysis Set population included all subjects who received at least 1 dose of the study drug. Here 'n' indicates the number of subjects analysed at specific time point.
End point type	Secondary
End point timeframe:	Day 1, 30 and 90

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: nM*minute				
arithmetic mean (standard deviation)				
Day 1 (n= 95, 93)	1443.25 (± 1870.763)	1719.53 (± 2008.222)		
Day 30 (n= 86, 91)	4253.18 (± 791.133)	3536.43 (± 1191.284)		
Day 90 (n= 83, 87)	4260.99 (± 861.846)	3576.43 (± 981.259)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: Thrombin Generation lag time

End point title	Pharmacokinetic or Pharmacodynamic Parameter: Thrombin
-----------------	--

End point description:

Safety Analysis Set population included all subjects who received at least 1 dose of the study drug. Here 'n' indicates the number of subjects analysed at specific time point.

End point type Secondary

End point timeframe:

Day 1, 30 and 90

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: minute				
arithmetic mean (standard deviation)				
Day 1 (n= 95, 93)	11.81 (± 17.218)	9.59 (± 14.157)		
Day 30 (n= 86, 91)	11.04 (± 2.786)	15.53 (± 6.389)		
Day 90 (n= 83, 87)	11.03 (± 2.392)	16.62 (± 9.242)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: Thrombin

End point title Pharmacokinetic or Pharmacodynamic Parameter: Thrombin

End point description:

Safety Analysis Set population included all subjects who received at least 1 dose of the study drug. Here 'n' indicates the number of subjects analysed at specific time point.

End point type Secondary

End point timeframe:

Day 1, 30 and 90

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: nM				
arithmetic mean (standard deviation)				
Day 1 (n= 95, 93)	178.07 (± 237.533)	204.97 (± 248.189)		
Day 30 (n= 86, 91)	494.87 (± 123.986)	357.59 (± 187.161)		
Day 90 (n= 83, 87)	509.97 (± 129.717)	346.45 (± 168.209)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: Thrombin time to peak

End point title	Pharmacokinetic or Pharmacodynamic Parameter: Thrombin time to peak
-----------------	---

End point description:

Change in Thrombin time to peak was evaluated as a part of Pharmacodynamic analysis. Safety Analysis Set 1 population included all subjects who received at least 1 dose of the study drug. Here 'n' indicates the number of subjects analysed at specific time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, 30 and 90

End point values	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: minute				
arithmetic mean (standard deviation)				
Day 1 (n= 95, 93)	7.15 (± 9.314)	7.96 (± 9.304)		
Day 30 (n= 86, 91)	15.73 (± 3.921)	21.49 (± 9.436)		
Day 90 (n= 83, 87)	15.48 (± 3.041)	22 (± 8.707)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetic or Pharmacodynamic Parameter: Thrombin velocity index

End point title	Pharmacokinetic or Pharmacodynamic Parameter: Thrombin velocity index
-----------------	---

End point description:

Change in Thrombin velocity index was evaluated as a part of Pharmacodynamic analysis. Safety Analysis Set population included all subjects who received at least 1 dose of the study drug. Here 'n' indicates the number of subjects analysed at specific time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1, 30 and 90

<b>End point values</b>	Clopidogrel	Edoxaban		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	100		
Units: nM/min				
arithmetic mean (standard deviation)				
Day 1 (n= 95, 93)	49.49 (± 72.482)	53.97 (± 71.745)		
Day 30 (n= 86, 91)	130.1 (± 68.48)	84.14 (± 65.21)		
Day 90 (n= 83, 87)	132.03 (± 70.044)	77.91 (± 64.268)		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From the signing of informed consent form up to end of the study (6 months)

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.1
--------------------	------

### Reporting groups

Reporting group title	Edoxaban
-----------------------	----------

Reporting group description:

Subjects administered with edoxaban 60 milligram (mg) once daily (QD) (two 30 mg tablets) for approximately 3 months on a background of aspirin 100 mg tablets QD.

Reporting group title	Clopidogrel
-----------------------	-------------

Reporting group description:

Subjects administered with a loading dose of clopidogrel 300 milligram (mg) (our 75-mg tablets) as first dose within 4 hours of hemostasis followed by 75 mg once daily (QD) (one 75 mg tablet) orally for a total of approximately 3 months on a background of aspirin 100 mg QD.

<b>Serious adverse events</b>	Edoxaban	Clopidogrel	
Total subjects affected by serious adverse events			
subjects affected / exposed	31 / 100 (31.00%)	30 / 101 (29.70%)	
number of deaths (all causes)	3	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma metastatic			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Femoral artery occlusion			
subjects affected / exposed	2 / 100 (2.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			

subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			
subjects affected / exposed	2 / 100 (2.00%)	4 / 101 (3.96%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	1 / 100 (1.00%)	3 / 101 (2.97%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	2 / 100 (2.00%)	2 / 101 (1.98%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	3 / 100 (3.00%)	2 / 101 (1.98%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	1 / 100 (1.00%)	2 / 101 (1.98%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			

subjects affected / exposed	2 / 100 (2.00%)	2 / 101 (1.98%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Necrosis</b>			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>Acute respiratory failure</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Epistaxis</b>			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Psychiatric disorders</b>			
<b>Alcohol Abuse</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
<b>Arterial restenosis</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Peripheral artery restenosis</b>			
subjects affected / exposed	3 / 100 (3.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Femur fracture</b>			

subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	0 / 100 (0.00%)	2 / 101 (1.98%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	4 / 100 (4.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	2 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	2 / 100 (2.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Angina pectoris			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			

subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac failure acute</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardio-respiratory arrest</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Cardiogenic shock</b>			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Coronary artery disease</b>			
subjects affected / exposed	2 / 100 (2.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Coronary artery stenosis</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
<b>Carotid artery stenosis</b>			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Haemorrhagic stroke</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Presyncope</b>			

subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>Iron deficiency anaemia</b>			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Anaemia</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>Intestinal Ischaemia</b>			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatobiliary disorders</b>			
<b>Cholelithiasis</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin and subcutaneous tissue disorders</b>			
<b>Skin Ulcer</b>			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
<b>Haematuria</b>			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure acute			

subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal tubular necrosis			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Compartment syndrome			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Clostridium colitis			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	2 / 100 (2.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Infected skin ulcer			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pneumonia			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Fluid Overload			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Edoxaban	Clopidogrel	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	77 / 100 (77.00%)	75 / 101 (74.26%)	
Vascular disorders			
Aortic dilatation			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Haematoma			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Femoral artery occlusion			
subjects affected / exposed	0 / 100 (0.00%)	2 / 101 (1.98%)	
occurrences (all)	0	2	
Hypertension			

subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences (all)	1	3	
Hypertensive crisis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Intermittent claudication			
subjects affected / exposed	2 / 100 (2.00%)	4 / 101 (3.96%)	
occurrences (all)	2	5	
Hypotension			
subjects affected / exposed	0 / 100 (0.00%)	2 / 101 (1.98%)	
occurrences (all)	0	2	
Peripheral artery stenosis			
subjects affected / exposed	3 / 100 (3.00%)	4 / 101 (3.96%)	
occurrences (all)	3	4	
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 100 (0.00%)	3 / 101 (2.97%)	
occurrences (all)	0	3	
Peripheral artery thrombosis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Peripheral coldness			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Raynaud's phenomenon			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Varicose vein			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Venous insufficiency			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Surgical and medical procedures			
Toe amputation			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	

Tooth extraction subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
General disorders and administration site conditions			
Calcinosis subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Asthenia subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	2 / 101 (1.98%) 2	
Chest pain subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	2 / 101 (1.98%) 2	
Chest discomfort subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Chills subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Fatigue subjects affected / exposed occurrences (all)	4 / 100 (4.00%) 5	1 / 101 (0.99%) 1	
Malaise subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Necrosis subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Non-cardiac chest pain subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Oedema peripheral subjects affected / exposed occurrences (all)	4 / 100 (4.00%) 4	1 / 101 (0.99%) 1	
Oedema			

subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 2	0 / 101 (0.00%) 0	
Pain subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	1 / 101 (0.99%) 1	
Pyrexia subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	1 / 101 (0.99%) 1	
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	1 / 101 (0.99%) 1	
Reproductive system and breast disorders Vaginal Haemorrhage subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	0 / 101 (0.00%) 0	
Dyspnoea subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	0 / 101 (0.00%) 0	
Cough subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	2 / 101 (1.98%) 2	
Emphysema subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Epistaxis subjects affected / exposed occurrences (all)	7 / 100 (7.00%) 12	7 / 101 (6.93%) 15	
Haemoptysis subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	

Nasal congestion subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Depression subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Drug dependence subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Insomnia subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Mental status changes subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Investigations			
Blood cholesterol increased subjects affected / exposed occurrences (all)	3 / 100 (3.00%) 3	0 / 101 (0.00%) 0	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	2 / 101 (1.98%) 2	
Blood pressure increased subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	2 / 101 (1.98%) 2	
Blood testosterone decreased			

subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Blood thyroid stimulating hormone increased		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Blood triglycerides increased		
subjects affected / exposed	3 / 100 (3.00%)	1 / 101 (0.99%)
occurrences (all)	3	1
Blood uric acid increased		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Carotid bruit		
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)
occurrences (all)	1	1
Creatinine renal clearance decreased		
subjects affected / exposed	6 / 100 (6.00%)	3 / 101 (2.97%)
occurrences (all)	6	3
Creatinine renal clearance increased		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Glycosylated haemoglobin increased		
subjects affected / exposed	2 / 100 (2.00%)	0 / 101 (0.00%)
occurrences (all)	2	0
Eosinophil count increased		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Haemoglobin decreased		
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)
occurrences (all)	1	1
Low density lipoprotein increased		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Lymphocyte percentage increased		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1

Neutrophil percentage increased subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Pedal pulse decreased subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Weight decreased subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
White blood cell count increased subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	1 / 101 (0.99%) 1	
Injury, poisoning and procedural complications			
Arterial restenosis subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Avulsion fracture subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Confusion postoperative subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Excoriation subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Contusion subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	4 / 101 (3.96%) 7	
Eye injury subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Fall subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	0 / 101 (0.00%) 0	
Foot fracture			

subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Fractured coccyx		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Incision site haemorrhage		
subjects affected / exposed	3 / 100 (3.00%)	0 / 101 (0.00%)
occurrences (all)	3	0
Limb injury		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Peripheral artery restenosis		
subjects affected / exposed	2 / 100 (2.00%)	2 / 101 (1.98%)
occurrences (all)	2	2
Overdose		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Post procedural haematoma		
subjects affected / exposed	6 / 100 (6.00%)	3 / 101 (2.97%)
occurrences (all)	6	3
Post procedural complication		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Post procedural haemorrhage		
subjects affected / exposed	1 / 100 (1.00%)	2 / 101 (1.98%)
occurrences (all)	1	2
Post procedural swelling		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Procedural pain		
subjects affected / exposed	2 / 100 (2.00%)	3 / 101 (2.97%)
occurrences (all)	2	3
Scratch		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Scrotal haematoma		

subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Spinal compression fracture subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Traumatic haematoma subjects affected / exposed occurrences (all)	4 / 100 (4.00%) 4	4 / 101 (3.96%) 4	
Subcutaneous haematoma subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Vascular pseudoaneurysm subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	2 / 101 (1.98%) 2	
Wound subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	1 / 101 (0.99%) 3	
Wound secretion subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Cardiac disorders			
Angina pectoris subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Atrial fibrillation subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Bradycardia subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Coronary artery stenosis subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	

Nervous system disorders			
Amputation stump pain			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Convulsion			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Dizziness			
subjects affected / exposed	5 / 100 (5.00%)	1 / 101 (0.99%)	
occurrences (all)	5	1	
Headache			
subjects affected / exposed	5 / 100 (5.00%)	0 / 101 (0.00%)	
occurrences (all)	5	0	
Hypoaesthesia			
subjects affected / exposed	2 / 100 (2.00%)	0 / 101 (0.00%)	
occurrences (all)	2	0	
Migraine			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Loss of consciousness			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Paraesthesia			
subjects affected / exposed	3 / 100 (3.00%)	1 / 101 (0.99%)	
occurrences (all)	3	1	
Neuropathy peripheral			
subjects affected / exposed	0 / 100 (0.00%)	2 / 101 (1.98%)	
occurrences (all)	0	2	
Sciatica			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences (all)	1	1	
Tremor			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Leukocytosis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Iron deficiency anaemia			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Thrombocytosis			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Normochromic Normocytic Anaemia			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences (all)	1	1	
Eye disorders			
Blepharitis			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Conjunctival haemorrhage			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences (all)	1	1	
Cataract			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Ocular hyperaemia			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Retinal tear			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Vision blurred			

subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 2	0 / 101 (0.00%) 0	
Abdominal pain subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	2 / 101 (1.98%) 3	
Abdominal distension subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Constipation subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	0 / 101 (0.00%) 0	
Dental caries subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	0 / 101 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	4 / 100 (4.00%) 4	2 / 101 (1.98%) 2	
Flatulence subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Dyspepsia subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Gastrointestinal angiodysplasia haemorrhagic subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Gastritis alcoholic			

subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Gastroesophageal reflux disease		
subjects affected / exposed	0 / 100 (0.00%)	2 / 101 (1.98%)
occurrences (all)	0	2
Haematemesis		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Gingival bleeding		
subjects affected / exposed	3 / 100 (3.00%)	0 / 101 (0.00%)
occurrences (all)	3	0
Haematochezia		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Haemorrhoidal haemorrhage		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Hiatus hernia		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Pancreatitis		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Stomatitis		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Rectal haemorrhage		
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)
occurrences (all)	1	2
Tooth loss		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Vomiting		
subjects affected / exposed	2 / 100 (2.00%)	1 / 101 (0.99%)
occurrences (all)	3	1
Nausea		

subjects affected / exposed occurrences (all)	6 / 100 (6.00%) 6	4 / 101 (3.96%) 5	
Hepatobiliary disorders			
Hepatic cirrhosis			
subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Dermal cyst			
subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Dermatitis			
subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Dermatitis contact			
subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Diabetic foot			
subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Eczema			
subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Ecchymosis			
subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	2 / 101 (1.98%) 3	
Hyperhidrosis			
subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Erythema			
subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	0 / 101 (0.00%) 0	
Increased tendency to bruise			

subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Ingrowing nail subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Neurodermatitis subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Night sweats subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Rash subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	2 / 101 (1.98%) 2	
Pruritus generalised subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Skin fissures subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Scab subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Skin ulcer subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	3 / 101 (2.97%) 5	
Renal and urinary disorders			
Chromaturia subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Nephrolithiasis subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	0 / 101 (0.00%) 0	
Haematuria subjects affected / exposed occurrences (all)	4 / 100 (4.00%) 5	4 / 101 (3.96%) 4	

Renal failure acute subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Renal failure subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Renal impairment subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	4 / 100 (4.00%) 4	1 / 101 (0.99%) 2	
Arthralgia subjects affected / exposed occurrences (all)	6 / 100 (6.00%) 6	2 / 101 (1.98%) 2	
Chondrocalcinosis pyrophosphate subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Costochondritis subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Flank pain subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Gouty arthritis subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Groin pain subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Joint swelling subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	2 / 101 (1.98%) 2	
Muscle spasms			

subjects affected / exposed occurrences (all)	3 / 100 (3.00%) 3	1 / 101 (0.99%) 1	
Musculoskeletal discomfort subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	0 / 101 (0.00%) 0	
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Musculoskeletal pain subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	2 / 101 (1.98%) 2	
Pain in extremity subjects affected / exposed occurrences (all)	9 / 100 (9.00%) 9	7 / 101 (6.93%) 8	
Myalgia subjects affected / exposed occurrences (all)	3 / 100 (3.00%) 3	0 / 101 (0.00%) 0	
Sensation of heaviness subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
<b>Infections and infestations</b>			
Bronchitis subjects affected / exposed occurrences (all)	1 / 100 (1.00%) 1	3 / 101 (2.97%) 3	
Cellulitis subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Gangrene subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Cystitis subjects affected / exposed occurrences (all)	0 / 100 (0.00%) 0	1 / 101 (0.99%) 1	
Gastroenteritis viral subjects affected / exposed occurrences (all)	2 / 100 (2.00%) 2	1 / 101 (0.99%) 1	

Herpes zoster			
subjects affected / exposed	1 / 100 (1.00%)	1 / 101 (0.99%)	
occurrences (all)	1	1	
Localised infection			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Nasopharyngitis			
subjects affected / exposed	4 / 100 (4.00%)	5 / 101 (4.95%)	
occurrences (all)	4	6	
Osteomyelitis			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Pharyngitis streptococcal			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Respiratory tract infection viral			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract infection			
subjects affected / exposed	2 / 100 (2.00%)	3 / 101 (2.97%)	
occurrences (all)	3	4	
Urinary tract infection			
subjects affected / exposed	4 / 100 (4.00%)	3 / 101 (2.97%)	
occurrences (all)	4	3	
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)	
occurrences (all)	1	0	
Gout			
subjects affected / exposed	1 / 100 (1.00%)	3 / 101 (2.97%)	
occurrences (all)	1	3	
Hyperglycaemia			

subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Hyperlipidaemia		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Hyperkalaemia		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Hypoglycaemia		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Hypokalaemia		
subjects affected / exposed	2 / 100 (2.00%)	1 / 101 (0.99%)
occurrences (all)	2	1
Hyponatraemia		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Hypomagnesaemia		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Obesity		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Multi-vitamin deficiency		
subjects affected / exposed	1 / 100 (1.00%)	0 / 101 (0.00%)
occurrences (all)	1	0
Type 2 diabetes mellitus		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1
Vitamin D deficiency		
subjects affected / exposed	0 / 100 (0.00%)	1 / 101 (0.99%)
occurrences (all)	0	1

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported